Participants that are plasma ctDNA positive with a genomic target will be assigned to one of the three groups in Arm 1 and receive genomically directed therapy.~Arm 1a: DNA Repair pathway = talazoparib + capecitabine (CLOSED)~Arm 1b: Immunotherapy pathway = atezolizumab + capecitabine~Arm 1c: PI3K Pathway = inavolisib + capecitabine ---> atezolizumab~Arm 1d: DNA Repair + Immunotherapy = talazoparib + atezolizumab + capecitabine~Participants that are plasma ctDNA positive without a genomic target will be assigned to Arm 2 and receive capecitabine or treatment of physician's choice.~Participants that are plasma ctDNA negative will be assigned to Arm 3 and receive any of the following based on patient and physician decision: no therapy/observation, capecitabine or treatment of physician's choice.
This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms based on plasma ctDNA positivity and genomic marker(s).